Wearable cardioverter defibrillator multicentre experience in a large cardiac surgery cohort at transient risk of sudden cardiac death.
Christian KühnStefan RuemkePhilipp RelleckeArtur LichtenbergDominik JoskowiakChristian HaglMohamed HassanRainer G LeyhStefan ErlerJens GarbadeSandra EifertPhilippe GrieshaberAndreas BoeningTorsten DoenstIlia VelichkovTomas MadejMichael KnautAndreas HainHeiko BurgerPublished in: European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery (2022)
The risk of sudden cardiac death is substantial within the first 3 months after cardiac surgery. Patients were protected effectively by WCD. Due to significant LVEF improvement, the majority did not require ICD implantation after WCD use. Compliance was high despite sternotomy. This multicentre experience confirms existing data regarding effectiveness, safety and compliance. Therefore, WCD should be considered in cardiac surgery patients with severely reduced LVEF.
Keyphrases
- cardiac surgery
- acute kidney injury
- end stage renal disease
- ejection fraction
- clinical trial
- newly diagnosed
- randomized controlled trial
- chronic kidney disease
- study protocol
- systematic review
- prognostic factors
- cross sectional
- electronic health record
- heart failure
- blood pressure
- big data
- deep learning
- aortic valve
- patient reported outcomes
- aortic stenosis
- atrial fibrillation
- patient reported
- transcatheter aortic valve replacement
- transcatheter aortic valve implantation